Dynavax Technologies Co. (NASDAQ:DVAX) Stock Holdings Lifted by Smartleaf Asset Management LLC

Smartleaf Asset Management LLC raised its position in Dynavax Technologies Co. (NASDAQ:DVAX) by 463.3% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,473 shares of the biopharmaceutical company’s stock after purchasing an additional 2,034 shares during the quarter. Smartleaf Asset Management LLC’s holdings in Dynavax Technologies were worth $32,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the company. Mizuho Markets Americas LLC grew its stake in Dynavax Technologies by 17.4% in the third quarter. Mizuho Markets Americas LLC now owns 1,379,582 shares of the biopharmaceutical company’s stock valued at $15,369,000 after purchasing an additional 204,475 shares in the last quarter. Bank of Montreal Can boosted its stake in shares of Dynavax Technologies by 8.3% during the 3rd quarter. Bank of Montreal Can now owns 1,077,081 shares of the biopharmaceutical company’s stock worth $11,848,000 after acquiring an additional 82,449 shares in the last quarter. Bank of New York Mellon Corp boosted its stake in shares of Dynavax Technologies by 4.4% during the 4th quarter. Bank of New York Mellon Corp now owns 931,328 shares of the biopharmaceutical company’s stock worth $11,893,000 after acquiring an additional 39,513 shares in the last quarter. Nordea Investment Management AB boosted its stake in shares of Dynavax Technologies by 42.7% during the 4th quarter. Nordea Investment Management AB now owns 777,816 shares of the biopharmaceutical company’s stock worth $10,034,000 after acquiring an additional 232,690 shares in the last quarter. Finally, Peregrine Capital Management LLC boosted its stake in shares of Dynavax Technologies by 1.8% during the 4th quarter. Peregrine Capital Management LLC now owns 654,620 shares of the biopharmaceutical company’s stock worth $8,359,000 after acquiring an additional 11,687 shares in the last quarter. Hedge funds and other institutional investors own 96.96% of the company’s stock.

Dynavax Technologies Price Performance

NASDAQ DVAX opened at $13.74 on Thursday. Dynavax Technologies Co. has a twelve month low of $9.74 and a twelve month high of $14.63. The company has a debt-to-equity ratio of 0.33, a quick ratio of 12.34 and a current ratio of 13.23. The stock has a market capitalization of $1.70 billion, a PE ratio of 76.33 and a beta of 1.23. The stock has a 50-day simple moving average of $13.08 and a 200 day simple moving average of $12.27.

Dynavax Technologies (NASDAQ:DVAX) last posted its quarterly earnings results on Thursday, February 20th. The biopharmaceutical company reported $0.05 EPS for the quarter, meeting the consensus estimate of $0.05. The firm had revenue of $72.03 million during the quarter, compared to analysts’ expectations of $72.70 million. Dynavax Technologies had a return on equity of 4.22% and a net margin of 9.85%. Research analysts anticipate that Dynavax Technologies Co. will post 0.32 EPS for the current year.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on the company. HC Wainwright reiterated a “buy” rating and set a $31.00 price target on shares of Dynavax Technologies in a research note on Friday, February 21st. StockNews.com upgraded Dynavax Technologies from a “hold” rating to a “buy” rating in a research note on Monday, February 24th. The Goldman Sachs Group downgraded Dynavax Technologies from a “neutral” rating to a “sell” rating and decreased their price target for the stock from $15.00 to $12.00 in a research note on Tuesday, February 11th. Finally, William Blair reissued an “outperform” rating on shares of Dynavax Technologies in a research report on Friday, February 21st.

About Dynavax Technologies

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.